Pathophysiology of acute graft-versus-host disease

Hematological Oncology

Volumn 21, Issue 4, 2003, Pages 149-161

  Reddy, Pavan ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

APC; CTL; Cytokines; NK cells; Th1; Th2

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; MONONUCLEAR PHAGOCYTE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

ACUTE DISEASE; ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0742270811     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.716     Document Type: Review

References (132)

1. Barnes D, Corp M, Loutit J, Neal F. Treatment of murine leukaemia with x-rays and homologous bone marrow: preliminary communication. Br Med J 1956; 2: 626-630.
2. Barnes D, Loutit J. Treatment of murine leukaemia with x-rays and homologous bone marrow. Br J Haematol 1957; 3: 241-252.
3. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966; 62: 21-78.
4. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001; 345: 1794-1800.
5. Erlich HA, Opelz G, Hansen J. HLA DNA typing and transplantation. Immunity 2001; 14: 347-356.
6. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg F. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. New Engl J Med 1996; 334: 281-285.
7. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157: 125-140.
8. Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of acute graft-vs.-host disease. In Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment, Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Marcel Dekker, Inc.: New York, 1990; 539-555.
9. Sale GE, Shulman HM. The Pathology of Bone Marrow Transplantation. Masson: New York, 1984.
10. Sale GE. Does graft-versus-host disease attack epithelial stem cells? Mol Med Today 1996: 114-119.
11. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295-304.
12. Truitt R, Johnson B, McCabe C, Weiler M. Graft versus leukemia. In Graft-vs-Host Disease (2nd edn), Ferrara J, Deeg H, Burakoff S (eds). Marcel Dekker, Inc.: New York, 1997; 385-424.
13. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
14. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
15. Chang RJ, Lee SH. Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of an la antigen on a murine macrophage cell line. J Immunol 1986; 137: 2853-2856.
16. Pober JS, Orosz CG, Rose ML. Can graft endothelial cells initiate a host anit-graft immune response. Transplantation 1996; 61: 343-349.
17. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305.
18. Cliff RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
19. Ringden O. Viral infections and graft-vs.-host disease. In Graft-vs. -Host Disease, Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Marcel Dekker: New York, 1990; 467.
20. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293: 293-297.
21. Teshima T, Ferrara JL. Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin Hematol 2002; 39: 15-22.
22. Hill G, Ferrara J. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
23. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Med 2002; 8: 575-581.
24. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
25. Ordemann R. Enhanced allostimulatory actvity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. JCI 2002; 109: 1249-1256.
26. Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res 2002; 4 (Suppl. 3): S127-S132.
27. Bromley SK, Burack WR, Johnson KG, et al. The immunological synapse. Annu Rev Immunol 2001; 19: 375-396.
28. Dustin ML. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 2001; 21: 258-263.
29. Murphy WJ, Blazar BR. New strategies for preventing graft-versus-host disease. Curr Opin Immunol 1999; 11: 509-515.
30. Ferrara J, Antin J. Pathophysiology of human GVHD. In Hematopoietic Cell Transplantation, Forman S, Blume K, Thomas E (eds). Blackwell Science, Inc.: New York, 1999; 305-315.
31. Korngold R, Sprent J. T cell subsets in graft-vs.-host disease. In Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment, Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Marcel Dekker-New York, 1990; 31-50.
32. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001; 344: 655-664.
33. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nature Med 2000; 6: 464-469.
34. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417-424.
35. Li XC, Strom TB, Turka LA, Wells AD. T cell death and transplantation tolerance. Immunity 2001; 14: 407-416.
36. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166: 973-981.
37. Van Parijs L, Ibraghimov A, Abbas AK. The roles of costimulation and Fas in T-cell apoptosis and peripheral tolerance. Immunity 1996; 4: 321-328.
38. Sykes M, Abraham VS. The mechanism of IL-2-mediated protection against GVHD in mice. II. Protection occurs independently of NK/LAK cells. Transplantation 1992; 53: 1063-1070.
39. Yang YG, Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Leuk Lymph 1999; 33: 409-420.
40. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001; 194: 1433-1440.
41. Wekerle T, Kurtz J, Sayegh M, et al. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001; 166: 2311-2316.
42. Drobyski WR, Komorowski R, Logan B, Gendelman M. Role of the passive apoptotic pathway in graft-versus-host disease. J Immunol 2002; 169: 1626-1633.
43. Drobyski WR, Gendelman M. Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. Leuk Lymph 2002; 43: 2011-2016.
44. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002; 99: 3083-3088.
45. Ho IC, Glimcher LH. Transcription: tantalizing times for T cells. Cell 2002; 109 (Suppl.): S109-S120.
46. Tseng SY, Dustin ML. T-cell activation: a multidimensional signaling network. Curr Opin Cell Biol 2002; 14: 575-580.
47. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001; 29: 259-277.
48. Hill G, Krenger W, Ferrara J. Cytokine dysregulation in acute graft-versus-host disease. Hematology 1998; 2: 423.
49. Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol 1993; 5: 565-572.
50. Jadus MR, Peck AB. Lethal murine graft-versus-host disease in the absence of detectable cytotoxic T lymphocytes. Transplantion 1983; 36: 281-289.
51. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. New Engl J Med 1992; 327: 1613-1617.
52. Ferrara JLM, Marion A, McIntyre JF, Murphy GF, Burakoff SJ. Amelioration of acute graft-versus-host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 1986; 137: 1874-1877.
53. Belanger C, Esperou-Bourdeau H, Bordigoni P, et al. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant 1993; 11: 293-297.
54. Anasetti C, Martin PM, Hansen JA, et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 1990; 50: 49-54.
55. Li XC, Demirci G, Ferrari-Lacraz S, et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nature Med 2001; 7: 114-118.
56. Kumaki S, Minegishi M, Fujie H, et al. Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children. Int J Hematol 1998; 67: 307-312.
57. Hill GR, Crawford JM, Cooke KJ, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft-versus-host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
58. Velardi A, Varese P, Terenzi A, et al. Lymphokine production by T-cell clones after human bone marrow transplantation. Blood 1989; 74: 1665-1672.
59. Niederwieser D, Herold M, Woloszczuk W, et al. Endogenous IFN-gamma during human bone marrow transplantation. Transplantation 1990; 50: 620-625.
60. Mowat A. Antibodies to IFN-gamma prevent immunological-mediated intestinal damage in murine graft-versus-host reactions. Immunology 1989; 68: 18-24.
61. Dickinson AM, Sviland L, Dunn J, Carey P, Proctor SJ. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro skin explant model. Bone Marrow Transplant 1991; 7: 209-216.
62. Klimpel GR, Annable CR, Cleveland MG, Jerrels TR, Patterson JC. Immunosuppression and lymphoid hypoplasia associated with chronic graft-versus-host disease is dependent upon IFN-γ production. J Immunol 1990; 144: 84-93.
63. Wall DA, Sheehan KC. The role of tumor necrosis factor-alpha and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation 1994; 57: 273-279.
64. Brochu S, Rioux-Masse B, Roy J, Roy DC, Perreault C. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease. Blood 1999; 94: 390-400.
65. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
66. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002; 196: 999-1005.
67. Ferrara JLM. Paradigm shift for graft-versus-host disease. Bone Marrow Transplant 1994; 14: 183-184.
68. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
69. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymph 2000; 38: 221-234.
70. Brok HPM, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451-6459.
71. Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 1990; 87: 5633-5637.
72. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995; 86: 2429-2438.
73. Murphy WJ, Welniak LA, Taub DD, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998; 102: 1742-1748.
74. Ellison CA, Fischer JMM, HayGlass KT, Gartner GJ. Murine graft-versus-host disease in a Fl-hybrid model using IFN-γ gene knockout donors. J Immunol 1998; 161: 631-640.
75. Welniak LA, Blazar BR, Wiltrout RH, Anver MR, Murphy WJ. Role of interleukin-12 in acute graft-versus-host disease (1). Transplant Proc 2001; 33: 1752-1753.
76. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85: 842-851.
77. Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J Immunol 1995; 154: 2687-2696.
78. Liu J, Anderson BE, Robert ME, et al. Selective T-cell subset ablation demonstrates a role for TI and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease. Blood 2001; 98: 3367-3375.
79. Reddy P, Teshima T, Hildebrandt G, et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 2002; 101: 2877-2885.
80. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 102: 115-123.
81. Zeng D, Lewis D, Dejbakhsh-Jones S, et al. Bone Marrow NK1.1- and NK1.1+ T Cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189: 1073-1081.
82. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000; 105: 1289-1298.
83. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
84. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant 2002; 8: 525-535.
85. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-406.
86. Taylor PA, Friedman TM, Komgold R, Noelle RJ, Blazar BR. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40: CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002; 99: 4601-4609.
87. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
88. Taylor PA, Friedman TM, Komgold R, Noelle RJ, Blazar BR. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40: CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002; 99: 4601-4609.
89. Tamada K, Tamura H, Flies D, et al. Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002; 109: 549-557.
90. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 1999; 104: 49-57.
91. Serody JS, Cook DN, Kirby SL, Reap E, Shea TC, Frelinger JA. Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood 1999; 93: 43-50.
92. Serody JS, Burkett SE, Panoskaltsis-Mortari A, et al. T-lymphocyte production of macrophage inflammatory protein-1 alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000; 96: 2973-2980.
93. New JY, Li B, Koh WP, et al. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant 2002; 29: 979-986.
94. Choi EY, Christianson GJ, Yoshimura Y, et al. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood 2002; 100: 4259-4264.
95. Zhang Y, Shlomchik WD, Joe G, et al. APCs in the liver and spleen recruit activated allogeneic CD8 + T cells to elicit hepatic graft-versus-host disease. J Immunol 2002; 169: 7111-7118.
96. Murai M, Yoneyama H, Ezaki T, et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nature Immunol 2003; 4: 154-160.
97. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
98. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323-370.
99. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645-2656.
100. Graubert TA, Russell JH, Ley T. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood 1996; 87: 1232-1237.
101. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/ granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997; 100: 904-911.
102. van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nature Rev Immunol 2002; 2: 273-281.
103. Ueno Y, Ishii M, Yahagi K, et al. Fas-mediated cholangiopathy in the murine model of graft-versus-host disease. Hepatology 2000; 31: 966-974.
104. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor-α antibodies on acute graft-versus-host disease pathologies. Blood 1998; 91: 4051-4055.
105. Kanda Y, Tanaka Y, Shirakawa K, et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant 1998; 22: 751-754.
106. Braun YM, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183: 657-661.
107. Martin PJ, Akatsuka Y, Hahne M, Sale G. Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood 1998; 92: 2177-2181.
108. Jiang Z, Podack E, Levy RB. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 2001; 98: 390-397.
109. Schmaltz C, Alpdogan O, Kappel BJ, et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nature Med 2002; 8: 1433-1437.
110. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
111. Murphy WJ, Koh CY, Raziuddin A, Bennett M, Longo DL. Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol Rev 2001; 181: 279-289.
112. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
113. Asai O, Longo DL, Tian Z, Homung RL, Taub DD, Ruscetti FW. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998; 101: 1835-1842.
114. Wang JW, Howson JM, Ghansah T, et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 2002; 295: 2094-2097.
115. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol 2001; 2: 675-680.
116. Nestel F, Kichian K, You-Ten K, Desbarats J, Price K, Lapp WS. The role of endotoxin in the pathogenesis of acute graft-versus-host disease. In Graft-vs-Host Disease (2nd edn), Ferrara JLM, Deeg HJ, Burakoff SJ (eds). M. Dekker, Inc.: New York, 1996.
117. Cooke K, Gerbitz A, Hill G, Crawford J, Teshima T, Ferrara JLM. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 7: 1581-1589.
118. Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 81: 1993-1999.
119. Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF. Apoptosis is a major form of cell injury in experimental acute graft-versus-host disease in skin and mucosa. J Invest Dermatol 1996; 106: 927.
120. Cooke K, Hill G, Gerbitz A, et al. TNFa Neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000; 70: 272-279.
121. Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2002; 97: 2886-2895.
122. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988; 141: 2629.
123. Abhyankar S, Gilliland DG, Ferrara JLM. Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation 1993; 56: 1518-1523.
124. Atkinson K, Matias C, Guiffre A, et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and 1L-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991; 77: 1376-1382.
125. Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999; 104: 459-467.
126. McCarthy PL, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915-1918.
127. Antin JH, Weisdorf D, Neuberg D, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002; 100: 3479-3482.
128. Langrehr JM, Murase N, Markus PM, et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 1992; 90: 679-683.
129. Weiss G, Schwaighofer H, Herold M. Nitric oxide formation as predictive parameter for acute graft-versus-host disease after human allogeneic bone marrow transplantation. Transplantation 1995; 60: 1239-1244.
130. Falzarano G, Krenger W, Snyder KM, Delmonte J, Karandikar M, Ferrara JLM. Suppression of B cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-α in mice with acute graft-versus-host disease. Blood 1996; 87: 2853-2860.
131. Krenger W, Falzarano G, Delmonte J, Snyder KM, Byon JCH, Ferrara JLM. Interferon-γ suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 1996; 88: 1113-1121.
132. Nestel FP, Greene RN, Kichian K, Ponka P, Lapp WS. Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. Blood 2000; 96: 1836-1843.